<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906369</url>
  </required_header>
  <id_info>
    <org_study_id>20-001670</org_study_id>
    <secondary_id>NCI-2021-04104</secondary_id>
    <secondary_id>20-001670</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04906369</nct_id>
  </id_info>
  <brief_title>Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring</brief_title>
  <official_title>Optimizing Treatment of Metastatic Breast Cancer Through Real-Time Disease Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates if blood tests can detect changes in disease status during treatment for&#xD;
      stage IV breast cancer. Information from this study may help researchers learn more about&#xD;
      metastatic breast cancer and how to optimize treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To identify subtype-specific signatures for breast cancer using genomic positioning of&#xD;
      plasma deoxyribonucleic acid (DNA) fragments.&#xD;
&#xD;
      II. To validate changes in circulating tumor-derived DNA (ctDNA) levels as a biomarker for&#xD;
      treatment monitoring in patients with metastatic breast cancer.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo collection of blood samples at baseline, 2 weeks after the start of&#xD;
      treatment, and at the beginning of each new treatment cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of patients with high circulating tumor-derived deoxyribonucleic acid (ctDNA) fractions (&gt; 50%)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will analyze across all three subtypes: Estrogen receptor positive (ER+), human epidermal growth factor receptor 2 positive (HER2+), and triple-negative breast cancer (TNBC). Will perform 30x whole genome sequencing (WGS) and generate subtype-specific pooled nucleosome occupancy maps. By comparing these maps with healthy volunteers, we will identify a set of loci across the genome most informative of cancer contribution in cell-free DNA (cfDNA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of treatment failure</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Defined as progression of disease on imaging studies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of shallow whole genome sequencing circulating tumor-derived DNA analysis results with available serologic tumor biomarkers used as a standard in clinical practice</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>shallow whole genome sequencing circulating tumor-derived DNA analysis results with available serologic tumor biomarkers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of immunity to target antigens and neoantitopes in metastatic breast cancer</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Anatomic Stage IV Breast Cancer AJCC v8</condition>
  <condition>Metastatic Breast Carcinoma</condition>
  <condition>Prognostic Stage IV Breast Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Ancillary-Correlative (biospecimen collection)</arm_group_label>
    <description>Patients undergo collection of blood samples at baseline, 2 weeks after the start of treatment, and at the beginning of each new treatment cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Ancillary-Correlative (biospecimen collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at Mayo Clinic Cancer Center that are undergoing treatment for stage IV breast&#xD;
        cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All women &gt; 18 years of age&#xD;
&#xD;
          -  Stage IV breast cancer undergoing cancer treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage I-III breast cancer&#xD;
&#xD;
          -  Unwilling or unable to give consent&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy, excluding non-melanoma skin cancers&#xD;
             and non-invasive cancers whose natural history or treatment does not have the&#xD;
             potential to interfere with the assessment of the investigational marker&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda J Ernst</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Brenda J. Ernst, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

